Loading…
TECX
Tectonic Therapeutic, Inc.
NASDAQ· Healthcare· Biotechnology
$35.62-2.94%
Key metrics
- Market cap
- $696.35M
- P/E
- —
- Forward P/E
- —
- P/B
- 2.9x
- Dividend yield
- —
- EPS
- -$4.57
- ROE
- -33.80%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.22
- 52-week high
- $39.53
- 52-week low
- $14.39
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
- 60
- Watertown, United States
Company description provided by Yahoo Finance.